tbuckley/cabot-search huggingface dataset:
Causative Mechanism of Constrictive Pericarditis Diagnosed by Fluoroscopy
Authors: Harpreet S. Bhatia, Ryan R. Reeves
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 17155: Mitral Annular Calcification Detected by Transthoracic Echocardiography is a More Robust Marker of Coronary Artery Calcification Than That Detected by Multidetector Computed Tomography
Authors: Hiroki Nishida, Haruhiko Abe, Kensuke Yokoi, Akiko Idemoto, Masayuki Nakamura, Yoshinori Iida, Chieko Toriyama, Tatsuhisa Ozaki, Kaori Yasumura, Taishi Kato, Kazuya Shinouchi, Tsuyoshi Mishima, Motoo Date, Yasunori Ueda, Masaaki Uematsu, Yukihiro Koretsune
Journal: Circulation (2017)

Introduction: Coronary artery calcification is a risk for coronary vascular event. Mitral annular calcification (MAC) is closely associated with coronary artery calcification. Although both transth...
Reply to Tine Hajdinjak and Nadja Kokalj-Vokač’s Letter to the Editor re: Re: Mecedes Marín-Aguilera, Lourdes Mengual, María José Ribal et al. Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. Eur Urol 2007;51:409–15 and Alan M. Nieder, Mark S. Soloway and Harry W. Herr. Should We Abandon the FISH Test? Eur Urol 2007;51:1469–71. Eur Urol 2007;52:287–9
Authors: Alan M. Nieder, Mark S. Soloway, Harry W. Herr
Journal: European Urology (2007)
INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC CHANGES IN ETHNIC MINORITY PATIENTS WITH COVID- 19 INFECTION
Authors: Preeti Jadhav, Bing Yue, Shoaib Ashraf, Sameer Kandhi, Siddharth Chinta, Shrestha Nikee, Harika Kalangi, Sunita Karki, Haozhe Sun, Jonathan N. Bella, Amandeep Singh
Journal: Journal of the American College of Cardiology (2021)
Abstract IA-012: Differential immunological effects of carbon-ion versus photon radiation therapy
Authors: Charles G. Drake
Journal: Clinical Cancer Research (2021)

Abstract Radiation therapy (RT) exerts multiple effects on the immune system; in particular RT can serve as an in situ vaccine to either prime new anti-tumor T cell responses, or to induce new responses. We and many others showed that these propitious effects appear to counter-balanced to some degree by immunosuppressive effects, including the expansion of regulatory T cells (Treg), recruitment of myeloid derived suppressive cells (MDSC), and induction of Trex which mitigates the pro-inflammatory effects of STING pathway activation. Carbon-ion radiation therapy (CiRT) is an emerging therapeutic modality based on data showing that heavy ions may improve dosimetry and decrease toxicity to normal tissues. Currently, CiRT is performed at a limited number of centers, thus its immunological effects remain relatively understudied. To address this knowledge gap, we used an orthotopic, syngenic murine model to compare the relative immunological effects of CiRT to conventional photon radiation therapy (PhRT). At short follow-up times post RT, PhRT decreased the prevalence of T cells in the TME at all doses examined, whilst CiRT appeared to be relatively lymphocyte sparing. Higher doses of CiRT increased the secretion of multiple pro-inflammatory cytokines to a greater degree than did PhRT. Consistent with our prior results, both modalities increased Treg infiltration; although this was less apparent with CiRT. Although these are early studies with several caveats, the results support the hypothesis that CiRT may have differential immunological effects than those mediated by PhRT. Citation Format: Charles G. Drake. Differential immunological effects of carbon-ion versus photon radiation therapy [abstract]. In: Proceedings of the AACR Virtual Special Conference on Radiation Science and Medicine; 2021 Mar 2-3. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(8_Suppl):Abstract nr IA-012.
Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events
Authors: Adam P. Bress, Tom Greene, Catherine G. Derington, Jincheng Shen, Yizhe Xu, Yiyi Zhang, Jian Ying, Brandon K. Bellows, William C. Cushman, Paul K. Whelton, Nicholas M. Pajewski, David Reboussin, Srinivasan Beddhu, Rachel Hess, Jennifer S. Herrick, Zugui Zhang, Paul Kolm, Robert W. Yeh, Sanjay Basu, William S. Weintraub, Andrew E. Moran
Journal: Journal of the American College of Cardiology (2021)
Anti Human CX3CR1 VHH Molecule Attenuates Venous Neointimal Hyperplasia of Arteriovenous Fistula in Mouse Model
Authors: Sanjay Misra, Sreenivasulu Kilari, Binxia Yang, Amit Sharma, Chih-Cheng Wu, Roberto I. Vazquez-Padron, John Broadwater
Journal: Journal of the American Society of Nephrology (2021)

Fractalkine receptor 1 (CX3CR1) mediates macrophage infiltration and accumulation, causing venous neointimal hyperplasia (VNH)/venous stenosis (VS) in arteriovenous fistula (AVF). The effect of blocking CX3CR1 using an anti-human variable VHH molecule (hCX3CR1 VHH, BI 655088) on VNH/VS was determined using a humanized mouse in which the human
Standard pleural interventions are not high-risk aerosol generating procedures
Authors: David T. Arnold, Florence K.A. Gregson, Sadiyah Sheikh, Fergus W. Hamilton, Hugh Welch, Alexandra Dipper, George W. Nava, James W. Dodd, Amelia O. Clive, Bryan R. Bzdek, Jonathan P. Reid, Nick A. Maskell
Journal: European Respiratory Journal (2021)

<b>Percutaneous pleural procedures should not be considered aerosol generating. This study should inform future iterations of guidelines on the appropriate use of PPE when performing these procedures.</b>https://bit.ly/3xFF71d
Cell therapy in patients with heart failure: a comprehensive review and emerging concepts
Authors: Roberto Bolli, Mitesh Solankhi, Xiang-Liang Tang, Arunpreet Kahlon
Journal: Cardiovascular Research (2021)

This review summarizes the results of clinical trials of cell therapy in patients with heart failure (HF). In contrast to acute myocardial infarction (where results have been consistently negative for more than a decade), in the setting of HF the results of Phase I-II trials are encouraging, both in ischaemic and non-ischaemic cardiomyopathy. Several well-designed Phase II studies have met their primary endpoint and demonstrated an efficacy signal, which is remarkable considering that only one dose of cells was used. That an efficacy signal was seen 6-12 months after a single treatment provides a rationale for larger, rigorous trials. Importantly, no safety concerns have emerged. Amongst the various cell types tested, mesenchymal stromal cells derived from bone marrow (BM), umbilical cord, or adipose tissue show the greatest promise. In contrast, embryonic stem cells are not likely to become a clinical therapy. Unfractionated BM cells and cardiosphere-derived cells have been abandoned. The cell products used for HF will most likely be allogeneic. New approaches, such as repeated cell treatment and intravenous delivery, may revolutionize the field. As is the case for most new therapies, the development of cell therapies for HF has been slow, plagued by multifarious problems, and punctuated by many setbacks; at present, the utility of cell therapy in HF remains to be determined. What the field needs is rigorous, well-designed Phase III trials. The most important things to move forward are to keep an open mind, avoid preconceived notions, and let ourselves be guided by the evidence.
Global Mental Health
Authors: Vikram Patel, Martin Prince
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US regulator says abortion pills can be dispensed by post—temporarily
Authors: Janice Hopkins Tanne
Journal: BMJ (2021)

The US Food and Drug Administration will allow American women to get the two pill medical abortion without visiting a clinic or medical office—at least during the pandemic.

They will be able to consult a doctor or other approved healthcare provider by telemedicine or telephone and receive their pills by post.1

The administration of President Joe Biden also moved to end the Trump administration’s ban on referrals for abortion by Title X, the federal government’s family planning programme.2

The moves follow petitioning by the American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine, the American Medical Association, the American Academy of Family Physicians, the Planned Parenthood Federation, and 16 other medical organisations. They wrote to Biden and Vice President Kamala Harris on 1 March, asking them to “take swift action to end …
Pain: Passion, Compassion, Sensibility
Authors: Vittal Katikireddi
Journal: BMJ (2004)

A Wellcome Trust exhibition at the Science Museum, London SW7, from 13 February until 20 June 2004. Admission free www.wellcome.ac.uk/pain www.sciencemuseum.org.uk/ Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> Pain. Pleasure. Religion. Catharsis. This exhibition considers all these things, but, above all, pain. “This exhibition is about the cultural place of pain and how science and other ways of thinking have shaped our beliefs, our understanding, and our attempts to control it,” explains the curator, Spanish philosopher Javier Moscoso. Moscoso has teamed up with the Science Museum and the Wellcome Trust to look at pain from its widest perspective. He explores not only the history of pain (including its evolution from antiquity to modernity), but also its effect on individuals and society. “The … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants
Authors: Zhaohui Du, Niels Weinhold, David Van Den Berg, Amie Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward S. Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Donglei Hu, John Graff, Sonja I Berndt, William J. Blot, John David Carpten, Graham Casey, Victoria L. Stevens, Rick Kittles, Goodman Phyllis, Anselm Hennis, Eric A. Klein, Barbara Nemesure, Benjamin A. Rybicki, Janet Stanford, John Witte, Christine B. Ambrosone, Esther M. John, Leslie Bernstein, Antoinette Stroup, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Elisa Bandera, Sue Ann Ingles, Jayesh Mehta, Graham A Colditz, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Loic Le Marchand, Kenneth C Anderson, Elad Ziv, Brian C.-H. Chiu, David Conti, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Jeffrey A Zonder, Gareth J. Morgan, Carol Ann Huff, Robert Z. Orlowski, Sagar Lonial, Christopher A. Haiman, Wendy Cozen
Journal: Blood (2017)
Teplizumab Improves Beta Cell Function, Delays Type 1 Diabetes
Authors: Jennifer Abbasi
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A methionine-Mettl3-N-methyladenosine axis promotes polycystic kidney disease
Authors: Harini Ramalingam, Sonu Kashyap, Patricia Cobo-Stark, Andrea Flaten, Chun-Mien Chang, Sachin Hajarnis, Kyaw Zaw Hein, Jorgo Lika, Gina M. Warner, Jair M. Espindola-Netto, Ashwani Kumar, Mohammed Kanchwala, Chao Xing, Eduardo N. Chini, Vishal Patel
Journal: Cell Metabolism (2021)
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Authors: S. Peters, U. Dafni, M. Perol, E. Felip, L. Polito, N. Pal, T.G.N. Ton, D. Merritt, S. Morris, R.A. Stahel
Journal: Annals of Oncology (2021)
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
Authors: Madan Jagasia, Aleksandr Lazaryan, Carlos R. Bachier, Amandeep Salhotra, Daniel J. Weisdorf, Behyar Zoghi, James Essell, Laurie Green, Olivier Schueller, Jeegar Patel, Alexandra Zanin-Zhorov, Jonathan M. Weiss, Zhongming Yang, David Eiznhamer, Sanjay K. Aggarwal, Bruce R. Blazar, Stephanie J. Lee
Journal: Journal of Clinical Oncology (2021)

The rho-associated coiled-coil-containing protein kinase-2 (ROCK2) signaling pathway regulates the Th17/regulatory T cells balance and controls profibrotic pathways. Selective ROCK2 inhibition with belumosudil (KD025) may offer a novel approach to the management of chronic graft-versus-host disease (cGVHD).
Reopening businesses and risk of COVID-19 transmission (vol 4, pg 67, 2021)
Authors: A. O'Donoghue, T. Dechen, W. Pavlova, M. Boals, G. Moussa, M. Madan, A. Thakkar, F. J. DeFalco, J. P. Stevens
Journal: npj Digital Medicine (2021)
To Understand the Disparities in Living Kidney Transplantation Outcomes, Look to the Community
Authors: J. Daryl Thornton
Journal: JAMA Network Open (2021)

S. Ali Husain, MD, MPH; Kristen L. King, MPH; Navin Sanichar, BA; R. John Crew, MD; Jesse D. Schold, PhD, MStat, MEd; Sumit Mohan, MD, MPH
Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia—Moving From Evidence to Practice—Reply
Authors: Areej El-Jawahri, Thomas W. LeBlanc, Jennifer S. Temel
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Authors: Kathleen N. Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A. Gold, Yolanda Garcia, Sudarshan K. Sharma, Christopher J. Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana Molinero, Vidya Maiya, Victor K. Khor, Yvonne G. Lin, Sandro Pignata
Journal: Journal of Clinical Oncology (2021)

To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC).This multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with newly diagnosed untreated International Federation of Gynecology and Obstetrics (FIGO) stage III or IV OC who either had undergone primary cytoreductive surgery with macroscopic residual disease or were planned to receive neoadjuvant chemotherapy and interval surgery. Patients were stratified by FIGO stage, Eastern Cooperative Oncology Group performance status, tumor immune cell PD-L1 staining, and treatment strategy and randomly assigned 1:1 to receive 3-weekly cycles of atezolizumab 1,200 mg or placebo (day 1, cycles 1-22), with paclitaxel plus carboplatin (day 1, cycles 1-6) plus bevacizumab 15 mg/kg (day 1, cycles 2-22), omitting perioperative bevacizumab in neoadjuvant patients. The co-primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat and PD-L1-positive populations.Between March 8, 2017, and March 26, 2019, 1,301 patients were enrolled. The median progression-free survival was 19.5 versus 18.4 months with atezolizumab versus placebo, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.07; stratified log-rank P = .28), in the intention-to-treat population and 20.8 versus 18.5 months, respectively (hazard ratio, 0.80; 95% CI, 0.65 to 0.99; P = .038), in the PD-L1-positive population. The interim (immature) overall survival results showed no significant benefit from atezolizumab. The most common grade 3 or 4 adverse events were neutropenia (21% with atezolizumab v 21% with placebo), hypertension (18% v 20%, respectively), and anemia (12% v 12%).Current evidence does not support the use of immune checkpoint inhibitors in newly diagnosed OC. Insight from this trial should inform further evaluation of immunotherapy in OC.
David Oliver: What price the Nolan principles for public office holders?
Authors: David Oliver
Journal: BMJ (2021)

In 1995 the UK government’s Committee on Standards in Public Life published seven principles for public office holders, commonly referred to as the Nolan principles,1 after the committee’s chair. These standards for ethical conduct were adopted and are still officially endorsed by the government. We still have a public standards committee. But events during the covid-19 pandemic make me question whether this is any more than paper talk—whether government ministers, their special advisers, and some public officials even pay lip service to the principles any longer.

In November 2020 the committee’s current chair, Jonathan Evans, delivered the Hugh Kay lecture, “Are we in a post-Nolan age?”2 He argued, “These principles are not a rulebook. They are a guide to institutional administration and personal conduct and are given a hard edge when they inform law, policy, procedure, and codes …
Evaluation of Time-Limited Trials Among Critically Ill Patients With Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments
Authors: Dong W. Chang, Thanh H. Neville, Jennifer Parrish, Lian Ewing, Christy Rico, Liliacna Jara, Danielle Sim, Chi-hong Tseng, Carin van Zyl, Aaron D. Storms, Nader Kamangar, Janice M. Liebler, May M. Lee, Hal F. Yee
Journal: JAMA Internal Medicine (2021)

For critically ill patients with advanced medical illnesses and poor prognoses, overuse of invasive intensive care unit (ICU) treatments may prolong suffering without benefit.
Asymmetrical facial flushing and sweating associated with anisocoria
Authors: Anna Michonidou, Denize Atan
Journal: BMJ (2021)

This is asymmetrical facial flushing in a man in his 20s with harlequin syndrome (fig 1).



Fig 1 

He was referred to the ophthalmology clinic with a six month history of painless anisocoria (right pupil smaller than …
Physical activity and sleep: An updated umbrella review of the 2018 Physical Activity Guidelines Advisory Committee report
Authors: Christopher E. Kline, Charles H. Hillman, Bonny Bloodgood Sheppard, Bethany Tennant, David E. Conroy, Richard F. Macko, David X. Marquez, Steven J. Petruzzello, Kenneth E. Powell, Kirk I. Erickson
Journal: Sleep Medicine Reviews (2021)